Holen Sie sich die Stockscreener-App
5.35
2.55%
-0.14
Vorhandelsmarkt:
5.48
0.13
+2.43%
Schlusskurs vom Vortag:
$5.49
Offen:
$5.6
24-Stunden-Volumen:
155.38K
Relative Volume:
0.46
Marktkapitalisierung:
$200.68M
Einnahmen:
$147.12M
Nettoeinkommen (Verlust:
$-33.88M
KGV:
-5.0362
EPS:
-1.0623
Netto-Cashflow:
$2.63M
1W Leistung:
-5.48%
1M Leistung:
+21.59%
6M Leistung:
-30.61%
1J Leistung:
-19.79%
1-Tages-Spanne:
$5.25
$5.67
1-Wochen-Bereich:
$5.25
$5.86
52-Wochen-Spanne:
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Firmenname
Lifecore Biomedical Inc
Sektor
Telefon
(952) 368-4300
Adresse
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
5.35 | 205.93M | 147.12M | -33.88M | 2.63M | -1.0623 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2025-09-04 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | Eingeleitet | William Blair | Outperform |
| 2024-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | Herabstufung | Stephens | Overweight → Equal-Weight |
Alle ansehen
Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten
Lifecore Biomedical signs manufacturing deal for neurology product - Investing.com
Lifecore Biomedical Signs Agreement for Tech Transfer and Commercial Production of Neurological Injectable Product - Quiver Quantitative
Seventh late-stage project adds neurology deal for Lifecore Biomedical - Stock Titan
LFCR Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Investor SentimentPreliminary Results - newsline.com
Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook - Yahoo Finance
Trading Systems Reacting to (LFCR) Volatility - Stock Traders Daily
Lifecore Biomedical (LFCR) director awarded 25,907 RSUs - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907-share restricted stock award - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907 restricted stock units - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907-share restricted stock unit grant - Stock Titan
Lifecore Shareholders Approve New 2026 Stock Incentive Plan - TipRanks
Lifecore Biomedical (NASDAQ: LFCR) wins approval for 2026 stock plan - Stock Titan
LFCR Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Rises Despite WeaknessAnnual Financial Report - newsline.com
Lifecore Biomedical Signs Tech Transfer Agreement for Ophthalmic - Contract Pharma
Lifecore Biomedical signs ophthalmic manufacturing deal - Investing.com UK
Lifecore Biomedical, Inc. Signs Manufacturing Services Agreement with Leading Provider of Ophthalmic Disease Management Solutions - marketscreener.com
Lifecore Biomedical signs ophthalmic manufacturing deal By Investing.com - Investing.com South Africa
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer - The Manila Times
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates by 75.6% as Revenue Remains UndisclosedBuyback Announcement Report - newsline.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical (LFCR) Inches Higher as Stock Approaches Key ResistanceVanna Flow - newsline.com
How The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 Expectations - Yahoo Finance
LFCR Q1 2026 Earnings: EPS Falls Short of Estimates as Losses WidenEarnings Season Outlook - The Legal Advocate
LFCR Q1 2026 Earnings: Significant EPS Miss Despite Positive Stock ReactionFinal Results - newsline.com
Lifecore Biomedical (LFCR) Declines 2.6%, Testing Key Support at $4.56Hull Moving Average - The Legal Advocate
LFCR Q1 2026 Earnings: Wider Loss Than Expected Despite Positive Stock ReactionGlobal Trading Community - Newser
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference - Sahm
Lifecore CEO, CFO to meet investors at June 2-4 Chicago conference - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 Earnings Miss by Significant: Key TakeawaysCollaborative Trading Signals - Newser
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
Lifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift - MSN
LFCR Stock Price, Quote & Chart | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore reaffirms 2026 guidance of $120M-$125M revenue and $20.5M-$25M adjusted EBITDA while targeting 12% revenue CAGR by 2029 - MSN
Lifecore Biomedical to Participate at CDMO Live Europe - The Manila Times
TradingKey - TradingKey
The sustainable advantages Lifecore Biomedical (LFCR) is developing (+0.42%) 2026-05-10Fast Rising Stocks - newser.com
Number of shareholders of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) price target decreased by 25.71% to 6.63 - MSN
LFCR Lifecore Biomedical shares slide 3.83% as Q1 2026 earnings miss estimates by 75.7% despite modest revenue growth.Social Momentum Signals - newser.com
The steady strength in Lifecore Biomedical (LFCR) story (Softens) 2026-05-08Company Analysis - newser.com
Lifecore Biomedical Q1 2026 Earnings Call Transcript - Sahm
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Maintains Target Price $6 - Moomoo
MSN Money - MSN
Lifecore Biomedical: Q1 Earnings Snapshot - theheraldreview.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-05-06 - Seeking Alpha
Lifecore Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Keybanc Initiates Coverage of Lifecore Biomedical (LFCR) with Sector Weight Recommendation - MSN
Lifecore Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifecore Biomedical Q1 Earnings Call Highlights - Yahoo Finance
Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):